Now with HRD* *Not available in Japan
Study relevant DNA and RNA cancer biomarkers from FFPE tumor tissue, now including HRD through an accessory kit to assess the Genomic Instability Score (GIS).
Batch up to 192 samples at a time while using the same panel content and tissue input type as the TruSight Oncology 500 assay.
Study liquid biopsies (blood) to assess circulating tumor DNA (ctDNA) with similar DNA panel content as the TruSight Oncology 500 assay.
*:연구 전용이며, 본 사양은 임상/진단 용도로 승인되지 않음.
Pan-Cancer Biomarkers NTRK1 NTRK2 NTRK3 MSI TMB | ||||||||
---|---|---|---|---|---|---|---|---|
Lung | Melanoma | Colon | Ovarian | Breast | Gastric | Bladder | Sarcoma | |
AKT1 | BRAF | AKT1 | BRAF | AKT1 | BRAF | MSH5 | ALK | |
ALK | CTNNB1 | BRAF | BRCA1 | AR | KIT | PMS2 | APC | |
BRAF | GNA11 | HRAS | BRCA2 | BRCA1 | KRAS | TSC1 | BRAF | |
DDR2 | GNAQ | KRAS | FOXL2 | BRCA2 | MET | CDK4 | ||
EGFR | KIT | MET | HRD | ERBB2 | MLH1 | CTNNB1 | ||
ERBB2 | MAP2K1 | MLH1 | KRAS | FGFR1 | PDGFRA | ETV6 | ||
FGFR1 | NF1 | MSH2 | PDGFRA | FGFR2 | TP53 | EWSR1 | ||
FGFR3 | NRAS | MSH6 | TP53 | HRD | FOXO1 | |||
KRAS | PDGFRA | NRAS | PIK3CA | GLI1 | ||||
MAP2K1 | PIK3CA | PIK3CA | PTEN | KJT | ||||
MET | PTEN | PMS2 | MDM2 | |||||
NRAS | TP53 | PTEN | MYOD1 | |||||
PIK3CA | SMAD4 | NAB2 | ||||||
PTEN | TP53 | NF1 | ||||||
RET | PAX3 | |||||||
TP53 | PAX7 | |||||||
PDGFRA | ||||||||
PDGFRB | ||||||||
SDHB | ||||||||
SDHC | ||||||||
SMARCB1 | ||||||||
TFE3 | ||||||||
WT1 |
The genes and biomarkers listed in this table are a subset of all genes included in the panel. To see the full gene list, view the product datasheet, available under Product Literature on the respective product pages.
The TruSight Oncology 500 Analytical Evaluation Service facilitates alignment with the latest CAP, AMP, and European standards. Use the service to evaluate analytical performance characteristics and integrate products into your workflows while reducing overall evaluation time by ~60%.
View Service